• 出版社/出版日：Mordor Intelligence / 2018年5月1日
|Single User（1名様用）||￥454,750 (USD4,250)||▷ お問い合わせ|
|Team User（7名様用）||￥481,500 (USD4,500)||▷ お問い合わせ|
|Corporate User||￥936,250 (USD8,750)||▷ お問い合わせ|
The global hormonal replacement therapy market is expected to register a CAGR of nearly 6.5% during 2018 to 2023 (the forecast period). Hormonal replacement therapies (HRTs) refers to the management of hormones in patients suffering from very low levels of hormones, due to diminished secretion in the body or no secretion in the body of an individual. The developed healthcare infrastructure and growing population of menopausal women and associated growth hormone deficiencies leads to the higher demand for hormone replacement therapy in the North American region.
Hormonal Imbalance Disorders with Increasing Geriatric Population
Hormonal imbalance disorders, with an increase in the geriatric population, is one of the major factors responsible for the growth of this market. With various kinds of hormonal changes, the female body predominantly gets affected by the natural process of aging, leading to abnormalities and diseases. Some of the common problems include – weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss. With growing age, ovaries produce lesser quantities of the hormones estrogen and progesterone. In the United States, up to 10% of women are diagnosed with polycystic ovary syndrome (PCOS), nearly 6% of married women below the age of 45 suffer from infertility, and nearly 8% men under the age of 45 receive fertility treatment by doctors during their lifetime. These associated factors with age lead to rising demand for HRT, thus driving the hormonal replacement therapy market.
Other factors, such as increasing awareness on post-menopausal issues among women and rise in drug development with novel delivery systems, lead to the growth of the market.
Substantial Risk of Cancer Associated with Hormone Replacement Therapy
The risk of cancer associated with the HRT certainly restricts the growth of this market. The combination HRT increases the risk of breast cancer by nearly 75%, even when used for a short period of time. The Cancer Research UK has shown in past that HRT increases the risk for several types of cancers, including uterus and ovarian cancers. Other disease risks include stroke, blood clots, and cardiac disorders. Thus, these risks associated with the HRT are hampering the growth of the hormonal replacement therapy market.
Other factors, such as high cost associated with the therapy, limit the accessibility of these treatments to middle-income families, which hampers the growth of the market.
US is expected to be the One of the Most Lucrative Regions in the Market
The United States is expected to have the largest market share in the forecast period. Growing geriatric population is one of the primary factors for the growth of the market. According to the National Institutes of Health (NIH), almost half of all postmenopausal women in the United States reported having used HRT at least once in their life. Women mostly preferred pills for HRT preparation. The healthy healthcare expenditure and technological advancements help in the growth of this market, making it one of the most lucrative regions, globally. Asia-Pacific is expected to grow with the highest rate in the forecast period, due to rising population base and growing awareness regarding HRT, particularly in India, China, and Japan.
Key Developments in the Market
• January 2018 – Ferring Pharmaceuticals announced the US FDA approval of Zomacton (somatropin) for replacement of growth hormone in adults with its deficiency.
Major Players – ABBOTT, BAYER AG, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE, HISAMITSU PHARMACEUTICAL CO INC, MERCK KGAA, MYLAN NV, NOVARTIS AG, NOVO NORDISK A/S AND PFIZER INC, amongst others.
Reasons to Purchase this Report
• Current and future of the global hormonal replacement therapy market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.レポート目次
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Awareness on Post-menopausal Issues among Women
6.1.2 Rise in Drug Development with Novel Delivery Systems
6.1.3 Hormonal Imbalance Disorders with Rising Geriatric Population
6.2 Market Restraints
6.2.1 High Cost of Hormone Replacement Therapy
6.2.2 Substantial Risk of Cancer Associated with Hormone Replacement Therapy
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapy
7.1.1 Estrogen Hormone Replacement
7.1.2 Growth Hormone Replacement
7.1.3 Thyroid Hormone Replacement
7.1.4 Testosterone Replacement
7.2 By Route of Administration
7.3 By Disease
7.3.3 Growth Hormone Deficiency
7.4 By Geography
7.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
7.4.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of the Middle East & Africa
7.4.5 South America
184.108.40.206 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Bayer AG
9.3 Eli Lilly and Company
9.4 F. Hoffmann-La Roche
9.5 Hisamitsu Pharmaceutical Co. Inc.
9.6 Merck KGaA
9.7 Mylan NV
9.8 Novartis AG
9.9 Novo Nordisk A/S
9.10 Pfizer Inc
9.11 List Not Exhaustive
10. Future of the Market